Annual report pursuant to Section 13 and 15(d)

CONSOLIDATED STATEMENTS OF OPERATIONS

v3.22.2.2
CONSOLIDATED STATEMENTS OF OPERATIONS - USD ($)
1 Months Ended 11 Months Ended 12 Months Ended
Dec. 31, 2021
Dec. 02, 2021
Dec. 31, 2020
Dec. 31, 2019
Financial Designation, Predecessor and Successor [Fixed List] Successor Predecessor Predecessor Predecessor
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 58,762,397 $ 578,602,418 $ 491,063,525 $ 145,482,112
OPERATING EXPENSES:        
Medical Expenses 66,877,005 592,465,049 484,502,423 141,029,737
Premium Deficiency Reserve 26,276,575 11,559,067 (20,539,364) 6,363,652
Corporate, General and Administrative Expenses 16,983,132 100,243,148 53,390,338 36,423,532
Sales and Marketing Expenses 364,127 1,818,015 1,502,634 801,685
Amortization of Intangible Assets 6,961,666 34,396    
Depreciation 187,558 1,540,335 795,172 399,177
TOTAL OPERATING EXPENSES 117,650,063 707,660,010 519,651,203 185,017,783
OPERATING LOSS (58,887,666) (129,057,592) (28,587,678) (39,535,671)
OTHER INCOME (EXPENSES):        
Interest Expense, net (1,321,922) (9,677,477) (2,533,180) (2,533,842)
Mark-to-Market of Stock Warrants 2,271,659 (7,664,869)    
Other     (290,684) 97,955
TOTAL OTHER INCOME (EXPENSE) 949,737 (17,342,346) (2,823,864) (2,435,887)
LOSS BEFORE INCOME TAXES (57,937,929) (146,399,938) (31,411,542) (41,971,558)
PROVISION FOR INCOME TAXES 0 0 0 0
NET LOSS (57,937,929) (146,399,938) (31,411,542) (41,971,558)
LESS NET LOSS ATTRIBUTABLE TO REDEEMABLE NON-CONTROLLING INTERESTS (47,856,729)      
NET LOSS ATTRIBUTABLE TO CONTROLLING INTERESTS $ (10,081,200) (146,399,938) (31,411,542) (41,971,558)
NET LOSS PER SHARE (BASIC) $ (0.24)      
NET LOSS PER SHARE (DILUTED) $ (0.24)      
Capitated Revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 57,224,539 567,735,297 480,739,577 139,332,707
Other Patient Service Revenue        
OPERATING REVENUE:        
TOTAL OPERATING REVENUE $ 1,537,858 $ 10,867,121 $ 10,323,948 $ 6,149,405